Nu-Med Plus Reports Q3 2025 Financial Results with Continued Net Loss and No Revenue

Nu-Med Plus, Inc. has reported its financial results for the third quarter of 2025, revealing a continued lack of revenue and a net loss of $11,966 for the three months ending September 30, 2025, compared to a net loss of $18,677 for the same period in 2024. For the nine months ended September 30, 2025, the company also reported no revenue, with a net loss of $43,564, an improvement from the $57,790 loss recorded in the prior year. The decrease in losses is attributed to a reduction in operating expenses, which fell to $10,075 in the third quarter from $17,417 in the same quarter of 2024, primarily due to lower professional fees.

As of September 30, 2025, Nu-Med Plus reported total assets of $5,048, a significant decrease from $9,373 at the end of 2024. Current liabilities increased to $263,708 from $224,469, leading to a working capital deficiency of $258,660. The company’s cash reserves also declined to $1,948, down from $2,373 at the end of the previous fiscal year. The accumulated deficit has grown to $9,936,896, reflecting the ongoing financial challenges faced by the company.

Strategically, Nu-Med Plus has focused on developing technologies utilizing nitric oxide for medical applications, including a hospital delivery system and a portable device for inhalation therapy. However, product development has been suspended pending additional capital infusion, which the company estimates will require approximately $1.2 million over the next twelve months. The company has relied on loans from related parties to cover operational expenses, with a note payable of $100,000 due by the end of 2025 and additional notes issued to related parties totaling $100,000.

Looking ahead, Nu-Med Plus acknowledges that without securing further financing, it may not be able to continue operations or advance its business plan. The company is currently funded through November 30, 2025, and anticipates needing $300,000 for corporate overhead and an additional $900,000 for ongoing product development. The management has expressed uncertainty regarding the timing and costs associated with bringing its products to market, particularly given the regulatory requirements for FDA approval. The company’s ability to execute its plans remains contingent on obtaining sufficient funding in the near future.